OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - IowaPolicy 05.01.17

Intravenous Immune Globulin (IVIG) therapy - Coverage Criteria

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Iowa Policy 05.01.17 alerts

Get alerted when Policy 05.01.17 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs medical necessity, prior authorization documentation, and coverage criteria for IVIG products for Wellmark Blue Cross and Blue Shield members; it applies to clinicians prescribing IVIG and to benefit determinations under member contracts.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyIntravenous Immune Globulin (IVIG) therapy - Coverage Criteria

Policy CodePolicy 05.01.17

Change TypeNo material clinical or coverage changes

Effective DateMay 22, 2026

Last ReviewApr 1, 2026

Next Review DateApr 1, 2026

Key ActionObtain prior authorization with indication-specific documentation (labs, diagnostics, and prior therapy history) before initiating IVIG.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

~37Listed uses

6 monthsTypical auth interval

1 monthShort auth examples

<400 mg/dLIgG threshold

~20Distinct indications

Coverage Criteria and Indication-Specific Authorization

inv-11: Multifocal Motor Neuropathy (MMN)

I. Multifocal Motor Neuropathy (MMN) — Initial and Reauthorization

ALL of the following

Initial authorization of 3 months may be granted when the following criteria are met:
ALL of the following
- Member experienced progressive, multifocal, asymmetrical weakness without objective sensory loss in 2 or more nerves for at least 1 month
- The diagnosis was confirmed by electrodiagnostic studies

ALL of the following

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyIntravenous Immune Globulin (IVIG) therapy - Coverage Criteria

Policy CodePolicy 05.01.17

Change TypeNo material clinical or coverage changes

Effective DateMay 22, 2026

Last ReviewApr 1, 2026

Next Review DateApr 1, 2026

Key ActionObtain prior authorization with indication-specific documentation (labs, diagnostics, and prior therapy history) before initiating IVIG.

SourceLink

On This Page

Prior Authorization, Documentation, and Denial Risks

Prior Authorization

Prior Authorization Required

Prior authorization is required for all indications. Submit complete documentation listed below at time of request; authorizations are time-limited and will be issued for the indication-specific durations noted in the Criteria for Approval section.

Authorizations are issued for specific durations by indication (e.g., 1 month, 2 months, 3 months, or 6 months) as specified in the "Criteria for Approval" section.
Re-authorization requires meeting the reauthorization criteria listed for the member's condition.

Documentation Required

Required Documentation for Prior Authorization

Provide the documentation elements relevant to the requested indication. Missing or incomplete documentation may result in denial or delay.

Primary immunodeficiency: serum IgG, IgA, IgM, IgG subclasses, vaccine response (post-pneumococcal titers), genetic/molecular testing (if applicable), lymphocyte subset enumeration, and IgG trough for those continuing therapy.
Myasthenia gravis and dermatomyositis/polymyositis: clinical records documenting standard treatments tried and failed.
CIDP/MMN: pre-treatment electrodiagnostic studies (EMG/NCS); CIDP—CSF analysis when available.
LEMS: neurophysiology studies and/or positive anti-P/Q voltage-gated calcium channel antibody test.
ITP: pre-treatment/current platelet counts and records of trial/failure with corticosteroid or anti-D therapy (unless contraindicated).
BMT/HSCT recipients: pre-treatment serum IgG level; requests within first 100 days post-transplant must be documented.
Parvovirus B19 PRCA: test confirming parvovirus B19 viremia.
Stiff-person syndrome: anti-GAD antibody testing and records of standard treatment trial and failure.
Autoimmune mucocutaneous blistering disease: biopsy and pathology report confirming diagnosis.

Denial Risk

Benefit and Contract Exclusions

Benefit determinations depend on the member's contract. Exclusions, limitations, or exceptions in the member's plan may result in denial even if medical criteria are met.

Verify member benefits and contract exclusions prior to authorization review.
Wellmark (Blue Cross Blue Shield - Iowa) will not determine medical necessity if the benefit does not exist or a contract exclusion applies.

Denial Risk

Lack of Demonstrated Reduction in Bacterial Infections May Prevent Re-authorization

For indications that require demonstration of reduced bacterial infections (e.g., primary immunodeficiency, CLL, pediatric HIV prophylaxis, BMT/HSCT recipients), re-authorization depends on documented reduction in serious bacterial infection frequency since initiation of IG therapy.

If reduction in frequency of bacterial infections is not demonstrated on re-authorization review, continuation may be denied.
Clinical documentation should include infection history, hospitalizations, IV antibiotic requirement, and IgG trough monitoring data.

Prior Authorization

BMT/HSCT Recipient Prior Authorization Constraints

BMT/HSCT recipients seeking IG for bacterial infection prophylaxis must meet timing or IgG thresholds at initiation of therapy to qualify for authorization.

IG requested within the first 100 days post-transplant is acceptable, OR
Pretreatment serum IgG < 400 mg/dL must be documented for eligibility when request is outside the 100-day window.

Denial Risk

Denial Risk for Unmet Criteria

IVIG will be considered not medically necessary and may be denied if the applicable initial or continuation criteria are not met.

Denial risk arises when required diagnostic confirmation, prior therapy trials, or documentation (e.g., biopsy, lab results, electrodiagnostics) are missing or inadequate.
Approvals may be subject to dosing limits consistent with FDA labeling, compendia, or evidence-based guidelines; excessive dosing requests may be limited.

Step Therapy

Requirement to Document Prior Standard Therapy

Providers must document trials of standard therapies as specified for certain autoimmune and hematologic indications before IG will be authorized.

Myasthenia gravis, dermatomyositis/polymyositis, stiff-person syndrome, autoimmune mucocutaneous blistering disease, and SLE require documentation that first-line (and where specified second-line) therapies were tried and failed or were contraindicated.
SLE: severe, active disease requires inadequate response, intolerance, or contraindication to first- and second-line therapies prior to authorization.

Documentation Required

Confirmation of Diagnosis Required

Confirm diagnosis-specific testing where required prior to approval.

LEMS: diagnosis must be confirmed by neurophysiology studies (e.g., EMG/NCS) or a positive anti-P/Q type voltage-gated calcium channel antibody test.
Autoimmune mucocutaneous blistering disease: diagnosis must be proven by biopsy with pathology report.
Provide diagnostic proof (e.g., genetic/molecular testing, EMG, CSF, antibody testing) as indicated for each condition.

Billing Rule

Coding and Billing Documentation

Use appropriate procedure and drug billing codes and ICD diagnosis codes on claims; include relevant documentation with prior authorization requests and retain for audit.

Report IG products using the listed HCPCS J-codes (e.g., J1459, J1552, J1553, J1556, J1557, J1561, J1566, J1568, J1569, J1572, J1554, J1599, J1576) and unclassified codes (J3490, J3590, C9399) when applicable.
Include appropriate CPT, revenue, and ICD-10 diagnosis codes consistent with the indication.

HCPCS / CPT / Documentation Thresholds

Listed HCPCS J-codes (group 1)HCPCS

J1459	Injection, immune globulin (Privigen), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1552	Injection, immune globulin (Alyglo), 500 mg (effective 1/1/2025)

Listed HCPCS J-codes (group 2)HCPCS

J1553	Injection, immune globulin (Yimmugo), 100 mg
J1556	Injection, immune globulin (Bivigam), 500 mg
J1557	Injection, immune globulin, (Gammaplex), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1561	Injection, immune globulin, (Gamunex), intravenous, non-lyophilized, (e.g., liquid), 500 mg
J1566	Injection, immune globulin, intravenous, lyophilized (e.g., powder), 500 mg
J1568	Injection, immune globulin, (Octagam), intravenous, non-lyophilized, (e.g., liquid), 500 mg
J1569	Injection, immune globulin, (Gammagard liquid), intravenous, non-lyophilized, (e.g., liquid), 500 mg
J1572	Injection, immune globulin, (Flebogamma), intravenous, non-lyophilized, (e.g., liquid), 500 mg
J1554	Injection, immune globulin, (Asceniv), 500 mg (effective 04/01/2021)
C9072	Injection, immune globulin (Asceniv), 500 mg (cancelled 04/01/2021)

1–10 of 14

1/2

Unclassified codesHCPCS

C9399

Unclassified drugs or biologicals (when specified as Qivigy [immune globulin intravenous, human-kthm])

inv-42: Pretreatment serum IgG — threshold values referenced

Pretreatment serum IgG threshold< 400 mg/dL — used as an initiation criterion for pediatric HIV prophylaxis and for BMT/HSCT prophylaxis (also cited for several other indications)

Contextual usesRequired for primary or secondary prophylaxis in pediatric HIV (pretreatment IgG < 400 mg/dL) and for BMT/HSCT recipients when either therapy is within 100 days post-transplant or pretreatment IgG < 400 mg/dL

Re-authorization relevanceRe-authorization decisions may reference initial pretreatment IgG levels (<400 mg/dL) when assessing ongoing need and infection frequency reduction

inv-43: Symptom duration/timing — MMN, GBS, BMT timing specifics

MMN timing criterionProgressive, multifocal, asymmetrical weakness without objective sensory loss in ≥2 nerves for at least 1 month (initial authorization of 3 months)

GBS timing criterionOnset of neurologic symptoms occurred less than 4 weeks from the anticipated start of therapy (authorization of 2 months total)

BMT/HSCT timing for prophylaxisIG requested within the first 100 days post-transplant qualifies as one of the timing criteria for initial authorization

inv-44: Total IgG threshold referenced elsewhere (< 400 mg/dL)

Total IgG thresholdTotal IgG < 400 mg/dL — used as an authorization trigger for hypogammaglobulinemia in multiple indications (e.g., HLH/MAS, CAR-T hypogammaglobulinemia, secondary immunosuppression)

Associated indicationsCited for HLH/MAS, hypogammaglobulinemia from CAR-T therapy, and secondary immunosuppression where IgG < 400 mg/dL supports authorization

Role in re-authorizationTotal IgG levels are used to document ongoing hypogammaglobulinemia and support continuation of therapy when below threshold

inv-45: Alternative hypogammaglobulinemia threshold — two standard deviations below mean for age

Alternative hypogammaglobulinemia definitionTwo standard deviations below the mean for age — accepted alternative criterion to low absolute IgG for authorization decisions

Where appliedUsed alongside absolute IgG thresholds (e.g., in HLH/MAS and primary immunodeficiency criteria such as CVID where ≥2 SD below mean for age qualifies)

Testing implicationRequires age‑adjusted reference ranges to determine whether IgG is ≥2 SD below the mean for age

inv-46: Platelet count threshold for adult HIV-associated thrombocytopenia (< 20,000/mcL)

Adult HIV-associated thrombocytopenia platelet thresholdPlatelet count < 20,000/mcL — criterion for authorization in adult HIV-associated thrombocytopenia (with significant bleeding and failure of RhIG in Rh-positive patients)

Pediatric vs adult distinctionPediatric HIV-associated thrombocytopenia criteria focus on IgG < 400 mg/dL plus clinical features; adults use the platelet count threshold (<20,000/mcL)

Authorization durationWhen criteria met (including platelet count <20,000/mcL), authorization may be granted for 6 months

Definitions, Background, and Appendices

Intravenous Immune Globulin (IVIG) is an immune globulin therapy used for a range of conditions including primary immunodeficiency disorders, selected autoimmune and inflammatory diseases, and certain prophylactic indications (for example, prophylaxis of bacterial infections in pediatric HIV or BMT/HSCT recipients). Coverage is aligned to FDA‑approved and accepted compendial uses and is conditioned on meeting the indication‑specific criteria, required documentation, and any applicable dosing constraints.

inv-66: FDA-Approved and Compendial Indications — list-style key facts

FDA-approved core indicationsIncludes primary immunodeficiency, idiopathic thrombocytopenic purpura (ITP), CIDP, multifocal motor neuropathy, Kawasaki syndrome, B-cell CLL, dermatomyositis

Compendial (off-label) common usesIncludes prophylaxis in pediatric HIV, BMT/HSCT prophylaxis, myasthenia gravis, Guillain-Barré syndrome, LEMS, F/NAIT, PRCA, stiff-person syndrome, immune checkpoint inhibitor toxicities, and more

ScopePolicy aligns coverage with FDA-approved indications and accepted compendial uses listed in the document

inv-67: Low IgG threshold referenced for some indications

Low IgG threshold referenced for some indicationsPretreatment or total IgG < 400 mg/dL is explicitly cited for pediatric HIV prophylaxis, BMT/HSCT prophylaxis, CAR-T–related hypogammaglobulinemia, and other indications

Used for both initiation and continuationIgG < 400 mg/dL may trigger initial authorization and is used in several re-authorization or continuation criteria

Alternate metricPolicy additionally allows two standard deviations below mean for age as an alternate definition of low IgG

inv-68: Hypogammaglobulinemia definition used in authorization decisions

Definition used for authorizationHypogammaglobulinemia generally defined as total IgG < 400 mg/dL or two standard deviations below the mean for age — used as an authorization trigger for several conditions (e.g., HLH/MAS, secondary immunosuppression, CAR-T)

Clinical contextsApplied in primary immunodeficiency evaluations (e.g., CVID criteria reference IgG thresholds) and in secondary causes such as CAR-T therapy or major surgery-associated immunosuppression

Documentation requirementAge‑adjusted IgG measurements or total IgG labs must be provided to support hypogammaglobulinemia claims

inv-69: Refractory opsoclonus-myoclonus — definition as last-resort use

Refractory opsoclonus-myoclonus definitionRefractory opsoclonus-myoclonus: disease not responsive to standard treatments — IVIG may be used as a last‑resort treatment (authorization of 6 months)

Paraneoplastic variantPolicy also authorizes IVIG for paraneoplastic opsoclonus-myoclonus-ataxia associated with neuroblastoma

Authorization noteUse described as last-resort for refractory cases when standard therapies have failed

inv-70: Impaired antibody response to pneumococcal vaccine — appendix definition and limits (hospital-initiated therapy exclusion noted elsewhere)

Impaired pneumococcal vaccine response (age limit)Defined for age ≥ 2 years: demonstrated impaired antibody response to pneumococcal polysaccharide vaccine; not established for children <2 years

Exclusion — hospital-initiated therapyAppendix A excludes therapy initiated in the hospital setting from this impaired antibody-response definition

Use in criteriaImpaired pneumococcal response is required for several primary immunodeficiency authorizations (see Appendix A) and must be documented with vaccine titers

inv-71: Risk factors for bleeding — examples listed for procedural planning

Examples of risk factors for bleedingUndergoing a medical or dental procedure with anticipated blood loss; comorbidities (e.g., peptic ulcer disease, hypertension); mandated anticoagulation therapy; professions or lifestyles predisposing to trauma (e.g., construction worker, firefighter, professional athlete)

PurposeProvided as examples to guide procedural planning when bleeding risk influences therapy decisions

ScopeAppendix B indicates list is not all-inclusive; clinical judgment needed for other bleeding risks